Ziegler, a specialty investment bank, advised Med Fusion in its recent sale to Quest Diagnostics. The transaction allowed Quest to acquire Med Fusion, creating a base in the southwestern U.S. for providing precision medicine diagnostics to aid cancer treatment and care.

Headquartered in Lewisville, TX, Med Fusion is an advanced diagnostics laboratory business providing support to a wide range of healthcare providers. The company is positioned to introduce more targeted precision medicine diagnostics for oncology and help enhance healthcare delivery system efficiencies.

In connection with the transaction, Quest is now a preferred provider to several organizations that were formerly owners of Med Fusion. These organizations include The US Oncology Network, Baylor Scott & White Health and Texas Oncology and Pathologists Bio-Medical Laboratories.

Dermot Shorten, SVP, Strategy, M&A and Ventures at Quest Diagnostics, said, “Ziegler was an important advisor in helping us to understand the full complexity of the two co-located laboratories and the various interrelationships with each owner-entity. This was a complicated transaction and Ziegler was up to the task of helping each party navigate their way to a successful result.”

Ziegler is a privately held investment bank, capital markets, wealth management and proprietary investments firm, celebrating its 115th anniversary this year.